Phase II data for DBV Technologies' Viaskin Milk shows significant response in a subgroup of kids with Milk allergy, Jefferies analyst Eun Yang tells investors in a research note. This is "highly encouraging" given the high natural resolution of milk allergy in kids and high placebo rates, Yang contends. She believes Viaskin continues to show safety and high compliance and estimates Viaskin Milk is worth $18 per share if successful in Phase III, versus $3 per share currently. The analyst keeps a Buy rating on DBV Technologies with a $37 price target.